Executives
?
Janda Kim
Director
Sorrento Therapeutics, Inc.
US, San Diego [HQ]
CIK
1518466
Data Source
We automatically created this profile. The information was aggregated based on earnings call transcripts, insider forms and DEF 14A statements.
Latest Information
Shares :
0
Price per Share :
$0.00
Equivalence :
$0.0
Transaction History
-
S0.0 Shares After TransactionValue : $n/aSold $31,260.00Transaction Date : 03/15/21
-
Footnotes
-
-
Footnotes:#1 This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person.
-
M6,000 Shares After TransactionValue : $24,000.00$12,000.00Transaction Date : 12/27/21
-
Footnotes
-
-
Footnotes:#1 This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person.
-
S3,000 Shares After TransactionValue : $17,640.00Sold $17,640.00Transaction Date : 12/27/21
-
Footnotes
-
-
Footnotes:#1 This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person.
-
M4,900 Shares After TransactionValue : $17,150.00$6,650.00Transaction Date : 04/12/21
-
Footnotes
-
-
Footnotes:#1 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $6.84 to $7.29, inclusive. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer or a security holder of the Issuer full information regarding the number of shares purchased or sold at each separate price.#2 This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on February 22, 2021.
-
S3,000 Shares After TransactionValue : $20,910.00Sold $13,243.00Transaction Date : 04/12/21
-
Footnotes
-
-
Footnotes:#1 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $6.84 to $7.29, inclusive. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer or a security holder of the Issuer full information regarding the number of shares purchased or sold at each separate price.#2 This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on February 22, 2021.